Since the emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), understanding the mechanisms underlying ...

Introduction Acute respiratory distress syndrome (ARDS) is a sudden and serious lung injury in the intensive care unit (ICU), which is characterized by deterioration of alveolar-vascular permeability ...

Doron Aronson Disclosures Expert Rev Cardiovasc Ther. 2012;10 (2):177-189.

Acute respiratory distress syndrome (ARDS) is a sudden and dangerous illness caused by other sudden medical or surgical conditions, such as sepsis, injury, burn or severe pancreatitis. 1 The symptoms ...

Objectives The purpose of this study was to examine the expectations of patients attending an urban primary care out-of-hours (OOH) facility with acute upper respiratory tract infection (acute URTI) ...

NORTH BRUNSWICK, N.J., June 17, 2025 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, announces that the U.S.

Cardiovascular disease is one of the main causes of mortality in developed countries, including countries in Asia. 1, 2 In recent years, with progress in acute coronary syndrome (ACS) treatment, ...

Fast Track status enables expedited regulatory review timelines and supports the development of recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases ...

BioAegis’ lead product, rhu-pGSN, is currently being studied in a 600-patient global Phase 2 trial for patients with moderate to severe Acute Respiratory Distress Syndrome (ARDS).

Acute respiratory distress syndrome (ARDS) is a very severe breathing problem with a high mortality rate (chance of dying). It has many potential causes, including viral infections such as COVID-19, ...